Metformin Hydrochloride Extended Release Tablets are being recalled for having more carcinogen NDMA than the FDA’s acceptable allowance. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant found in water and foods, including meats, dairy products, and vegetables.1 With levels above admissible according to the FDA it is being recalled ensuring no adverse reactions arise during consumption. If any adverse reactions are experienced you can submit them online here or find more information on how to mail or fax here. Many different retailers might be involved so it is important to check your label and bottle.
What products are being recalled?
Metformin HCl Extended Release Tablets, USP, 500 mg and 750 mg, manufactured by Amneal, are being recalled. They are the prescription, solid oral products that are indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.1
The Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, subject to the recall, are identified by the NDC numbers stated on the product label.
Metformin HCl Extended Release Tablets, USP, 500 mg
Metformin HCl Extended Release Tablets, USP, 750 mg
*Amneal’s Metformin Hydrochloride Immediate Release Tablets, USP are not affected by this recall.1
Metformin HCI Extended Release Tablets manufactured by Bayshore Pharmaceuticals, LLC are also being recalled.
Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg lots subject to the recall are identified in the table below.
Metformin Hydrochloride Extended-Release Tablets manufactured by Marksans Pharma Limited, are being recalled due to the detection of N-Nitrosodimethylamine (NDMA) impurity.
Time-Cap Labs Inc. Metformin Hydrochloride for Extended-Release Tablets, USP 500 mg and 700 mg lots subject to the recall are identified below.
Metformin Hydrochloride Extended-Release Tablets, USP 500mg:
90 counts: 49483-623-09 100 counts: 49483-623-01 500 counts: 49483-623-50 1000 counts: 49483-623-10
Metformin Hydrochloride Extended-Release Tablets, USP 750mg:
100 counts: 49483-624-01
Because Metformin is used to treat serious medical conditions, patients taking the recalled Metformin should continue taking their medicine until they have a replacement product.
To determine whether a specific product has been recalled, patients should look at the drug name and company name on the label of their prescription bottle. If the information is not on the bottle, patients should contact the pharmacy that dispensed the medicine.
Patients should also contact their health care professional (the pharmacist who dispensed the medication or doctor who prescribed the medication) if their medicine is included in this recall to discuss their treatment, which may include another product not affected by this recall or an alternative treatment option.
#medications #MetforminHydrochloride #Diabetescare #Pharmacist #AmnealMetformin #Diabetesmanagement #Recall #BayshorePharmaceuticals #MedicationRecall #Pharmacycare #Amneal #medicationmanagement #metformin